Previous 10 | Next 10 |
2023-05-12 07:02:02 ET Bio-Path press release ( NASDAQ: BPTH ): Q1 GAAP EPS of -$0.66 misses by $0.34 . As of March 31, 2023, the Company had cash of $6.7 million, compared to $10.4 million as of December 31, 2022. For further details see: Bio-Path GAAP EPS o...
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results...
HOUSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live c...
Dallas, Texas--(Newsfile Corp. - April 10, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_Q422.pdf To view the full announcement, including downloadable images, bios, and more, click h...
2023-03-31 10:25:05 ET Bio-Path Holdings Inc. (BPTH) Q4 2022 Earnings Conference Call March 31, 2023 08:30 AM ET Company Participants Will O'Connor - Stern IR Peter Nielsen - CEO and CFO Anthony Price - SVP, Finance, Accounting and Administration Conference...
2023-03-31 07:02:55 ET Bio-Path press release ( NASDAQ: BPTH ): Q4 GAAP EPS of -$1.91 misses by $1.46 . As of December 31, 2022, the Company had cash of $10.4 million, compared to $23.8 million at December 31, 2021. Net cash used in operating activities for the yea...
HOUSTON, March 31, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial resul...
HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live...
HOUSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical developme...
HOUSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the enrollment and dosing...
News, Short Squeeze, Breakout and More Instantly...
Bio-Path Holdings Inc. Company Name:
BPTH Stock Symbol:
NASDAQ Market:
Bio-Path Holdings Inc. Website:
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnolog...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...